Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.
Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Trinh QD, Nguyen PL. Mahal BA, et al. Among authors: sweeney cj. Prostate Cancer Prostatic Dis. 2014 Sep;17(3):273-9. doi: 10.1038/pcan.2014.23. Epub 2014 Jul 1. Prostate Cancer Prostatic Dis. 2014. PMID: 24980272
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA. Pettersson A, et al. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509. doi: 10.1158/1055-9965.EPI-12-0042. Epub 2012 Jun 26. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22736790 Free PMC article.
SPINK1 protein expression and prostate cancer progression.
Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA. Flavin R, et al. Clin Cancer Res. 2014 Sep 15;20(18):4904-11. doi: 10.1158/1078-0432.CCR-13-1341. Epub 2014 Mar 31. Clin Cancer Res. 2014. PMID: 24687926 Free PMC article.
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA, Feldman H, O'Donnell E, Mahal BA, Perez V, Howard S, Rosenthal M, Cheng SC, Nguyen PL, Beard C, D'Amico AV, Sweeney CJ. Lago-Hernandez CA, et al. Among authors: sweeney cj. Ann Oncol. 2015 Jul;26(7):1396-401. doi: 10.1093/annonc/mdv180. Epub 2015 Apr 17. Ann Oncol. 2015. PMID: 25888612 Free PMC article.
Chemotherapy for metastatic castrate-sensitive prostate cancer.
Miller RE, Sweeney CJ. Miller RE, et al. Among authors: sweeney cj. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):139-44. doi: 10.1038/pcan.2016.10. Epub 2016 Mar 15. Prostate Cancer Prostatic Dis. 2016. PMID: 26976365 Review.
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK. McKay RR, et al. Cancer. 2016 Aug 1;122(15):2389-98. doi: 10.1002/cncr.30056. Epub 2016 May 19. Cancer. 2016. PMID: 27198170 Free PMC article. Clinical Trial.
274 results